A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
NCT01133509
Unknown
In this pilot study, we intend to demonstrate that a great portion of women at high risk (inadequate screening, HPV 16/18 and/or cytology) are presenting to the ED, cytology/ HPV testing via ThinPrep®Pap testTM and surveillance. We intend to provide improved access to healthcare and monitoring through administration of vaccine to eligible patients and 1 year follow up for patients involved in this study. Females meeting inclusion/exclusion criteria participating in the study (n=100) that have n... Read More
Gender:
FEMALE
Ages:
Between 18 years and 26 years
Trial Updated:
08/21/2012
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Genital Human Papilloma Virus Infection
Register for Updates
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
NCT00319592
Completed
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains after completion of vaccination course.
Gender:
ALL
Ages:
Between 18 years and 48 years
Trial Updated:
08/16/2012
Locations: Clinical Pharamacology Center, Lenexa, Kansas
Conditions: Japanese Encephalitis
Register for Updates
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
NCT00978120
Completed
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in people with asthma. The study will enroll 350, and possibly up to 400 healthy adults ages 12 and older with mild, moderate, or severe asthma. Participants will be randomly assigned to 1 of 2 possible vaccine groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1 vaccine given as two 15 mcg injections. Both... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/08/2012
Locations: Emory University, Atlanta, Georgia +6 locations
Conditions: H1N1 Influenza Virus
Register for Updates
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
NCT00514072
Unknown
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/08/2012
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates
Sanofi H1N1 + TIV - Adults and Elderly
NCT00943878
Completed
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine against the 2009 H1N1 virus. This study will help determine how the H1N1 flu shot should be given with the seasonal flu shot to make it most effective. Participants will include up to 850 healthy adults, ages 18 and older. Participants will receive 2 H1N1 vaccines in addition to placebo (inactive substance) and the seasonal flu shot over 3 study visits... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2012
Locations: Emory Vaccine Center - The Hope Clinic, Decatur, Georgia +4 locations
Conditions: Influenza
Register for Updates
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
NCT00976027
Terminated
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of laboratory-confirmed influenza caused by viral types/subtypes that are antigenically similar to those contained in the respective annual vaccine formulations. Secondary objectives: * To compare the clinical efficacy of Fluzone High Dose vaccine with that of Fluzone® vaccine in elder... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2012
Locations: Not set, Birmingham, Alabama +97 locations
Conditions: Influenza
Register for Updates
PR1 Vaccination in Myelodysplastic Syndrome (MDS)
NCT00893997
Terminated
Primary aim: 1. To determine the immunologic response, using a PR1-HLA-A2 tetramer assay, to 4 subcutaneous (SQ) injections of TVC-PR1 vaccine formulated in Montanide ISA 51 VG followed by granulocyte macrophage colony-stimulating factor (GM-CSF) in low risk and intermediate-1 myelodysplastic syndrome (MDS) patients. Secondary aims: 1. To determine if non-immunologic responders to 4 subcutaneous (SQ) injections of TVCPR1 vaccine formulated in Montanide ISA 51 VG followed by GM-CSF can be conv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2012
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Myelodysplastic Syndrome
Register for Updates
Study Evaluating Pneumococcal Vaccine in Healthy Infants
NCT00205803
Completed
The purpose of this study is to evaluate the safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in healthy infants. This is the first study with this vaccine in infants.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
07/06/2012
Locations: Not set, New York, New York
Conditions: Healthy Subjects, Pneumococcal Infections
Register for Updates
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
NCT00722839
Completed
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/21/2012
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Nonneoplastic Condition
Register for Updates
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
NCT00045617
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +99 locations
Conditions: Lung Cancer
Register for Updates
Study of Anti-HIV Therapy Intensification
NCT00034086
Completed
The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe. Patients who take part in A5136 are also eligible to take part in 2 substudies. The purpose of substudy A5140s is to see how many latently infected cells (cells in which the HIV virus survives) are in the lymph node (small, rounded structures that make disease-fighting cells). Substud... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/17/2012
Locations: University of Colorado Hospital CRS, Aurora, Colorado +2 locations
Conditions: HIV Infections
Register for Updates
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
NCT01102114
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Encino, California +24 locations
Conditions: Smoking Cessation
Register for Updates